Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Litza McKenzie"'
Autor:
Samit R. Joshi, Disala Fernando, Stephanie Igwe, Litza McKenzie, Anu S. Krishnatry, Fiona Halliday, Joyce Zhan, Thomas J. Greene, Jianfeng Xu, Geraldine Ferron‐Brady, Max Lataillade, Sherene Min
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 6, Pp n/a-n/a (2020)
Abstract Despite advances in HIV‐1 management with antiretroviral therapy, drug resistance and toxicities with multidrug regimens can result in treatment failure. Hence, there is a continuing demand for antiretroviral agents (ARVs) with novel mecha
Externí odkaz:
https://doaj.org/article/cb56c5de98f44634b415509c7f6e6e7f
Autor:
Tamás Jordán, Orsolya Basa-Dénes, Réka Angi, János Orosz, Zsolt Ötvös, Andrea Ujhelyi, Genovéva Filipcsei, László Molnár, Tamás Solymosi, Hristos Glavinas, Dominic Capone, Nicola Whitfield, John McDermott, Litza McKenzie, Lauren Shurety, Elizabeth Manning Duus
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2171 (2021)
Currently approved formulations of the androgen synthesis inhibitor abiraterone acetate (AA) consist of multiple tablets administered daily in a fasted state. Removing the food effect and switching to a suspension formulation is expected to improve t
Externí odkaz:
https://doaj.org/article/757219b1771c4087aac504ec8c9247cf
Autor:
Kathy Abbott-Banner, Debra J. Tompson, Vanessa Zann, Litza McKenzie, Simon Hawkins, Teresa Fuller, Mark Whitaker, Marcy Powell, Geoffrey Johnson, Rennan Pan
Publikováno v:
Pharmaceutical Research
Purpose GSK2982772 is a selective inhibitor of receptor-interacting protein kinase-1, with a 2–3 h half-life. This study evaluated if a once-daily modified-release formulation of GSK2982772 could be developed with no significant food effect. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a4ab729d8923177a6a2179749770bee
https://doi.org/10.1007/s11095-021-03059-z
https://doi.org/10.1007/s11095-021-03059-z
Autor:
Debra Tompson, Mark Whitaker, Rennan Pan, Geoffrey Johnson, Teresa Fuller, Vanessa Zann, Litza McKenzie, Kathy Abbott-Banner, Simon Hawkins, Marcy Powell
Publikováno v:
Pharmaceutical research. 39(1)
Purpose GSK2982772 is a selective inhibitor of receptor-interacting protein kinase-1 (RIPK1) with a short 2- to 3-h half-life. In a previous modified-release (MR) study, a matrix monolithic formulation (80% GSK2982772 released over 12 h) provided a o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::437d79796299ef97c8386fd975eba959
https://pubmed.ncbi.nlm.nih.gov/34988780
https://pubmed.ncbi.nlm.nih.gov/34988780
Autor:
Thomas J Greene, Sherene Min, Max Lataillade, Joyce Zhan, Samit R Joshi, Fiona Halliday, Stephanie Igwe, Geraldine Ferron-Brady, Litza McKenzie, Jianfeng Xu, Anu Shilpa Krishnatry, Disala Fernando
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 8, Iss 6, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives, Vol 8, Iss 6, Pp n/a-n/a (2020)
Despite advances in HIV‐1 management with antiretroviral therapy, drug resistance and toxicities with multidrug regimens can result in treatment failure. Hence, there is a continuing demand for antiretroviral agents (ARVs) with novel mechanisms of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de8ed81d4d7280c7e0c83b7389d7b493
https://pubmed.ncbi.nlm.nih.gov/33200887
https://pubmed.ncbi.nlm.nih.gov/33200887
Autor:
Gary Layton, Aidan K Curran, Perry Jason M, Pauline Bedwell, Lisa Tan, Katie Kane, Dennis Henderson, Dave Singh, Lucy Connor, Naimat Khan, Litza McKenzie, Patrick J Johnson, David L. Hava, James Roach, Clarie Swann, Steve Kramer
Publikováno v:
Br J Clin Pharmacol
Aims Oral itraconazole has variable pharmacokinetics and risks of adverse events associated with high plasma exposure. An inhalation formulation of itraconazole (PUR1900) is being developed to treat allergic bronchopulmonary aspergillosis, an allergi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83eecb4856fec17c279879de7deafe96
https://pubmed.ncbi.nlm.nih.gov/31696544
https://pubmed.ncbi.nlm.nih.gov/31696544
Autor:
Chris Roe, Litza McKenzie, Gábor Heltovics, Tamás Solymosi, Hristos Glavinas, Orsolya Basa-Dénes, Balázs Kárpáti, Réka Angi, Tamás Jordán, John McDermott
Publikováno v:
Journal of Clinical Oncology. 36:e16555-e16555
e16555Background: Rapamune (Sirolimus) exhibits low bioavailability and high variability following oral administration. Reaching the therapeutic blood concentrations in renal cancer patients was fo...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03c9b4a139d3156f3788198b723db203
https://doi.org/10.1200/jco.2018.36.15_suppl.e16555
https://doi.org/10.1200/jco.2018.36.15_suppl.e16555